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Cyclophosphamide for suspected primary angiitis of the central
nervous system in a patient with human immunodeficiency
virus: A case report
Martha M. Rumore, Samantha Su, Jake Pellinen
ABSTRACT
Introduction: Central nervous system (CNS) vasculitis is rare, including in human
immunodeficiency virus (HIV), occurring in less than 1% of patients. Systemic vasculitis affecting
the CNS is termed secondary CNS vasculitis, whereas primary CNS vasculitis, referred to as
primary angiitis of the CNS (PACNS) refers to an extremely rare disease specifically confined to
the CNS. Only some cases of PACNS in HIV patients have been reported in literature.
Case Report: We report a case of a 46-year-old female with HIV who developed probable primary
CNS vasculitis, which was treated with intravenous cyclophosphamide and glucocorticoids
for both induction and maintenance. A systematic literature review regarding PACNS and its
therapeutic management is presented in this report. There were no clinical trials for PACNS.
Based on the American Academy of Neurology (AAN) classes of evidence for therapeutic
effectiveness, most data is of intermediate or weak strength.
Conclusion: This case highlights diagnostic and clinical features of PACNS and provides
an overview of the current literature regarding pharmacotherapy. Further case reports and
additional studies are needed.
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Cyclophosphamide for suspected primary angiitis of
the central nervous system in a patient with human
immunodeficiency virus: A case report
Martha M. Rumore, Samantha Su, Jake Pellinen

ABSTRACT
Introduction:
Central
nervous
system
(CNS) vasculitis is rare, including in human
immunodeficiency virus (HIV), occurring in less
than 1% of patients. Systemic vasculitis affecting
the CNS is termed secondary CNS vasculitis,
whereas primary CNS vasculitis, referred to as
primary angiitis of the CNS (PACNS) refers to
an extremely rare disease specifically confined
to the CNS. Only some cases of PACNS in HIV
patients have been reported in literature. Case
Report: We report a case of a 46-year-old female
with HIV who developed probable primary CNS
vasculitis, which was treated with intravenous
cyclophosphamide and glucocorticoids for
both induction and maintenance. A systematic
literature review regarding PACNS and its
therapeutic management is presented in this
report. There were no clinical trials for PACNS.
Based on the American Academy of Neurology
(AAN) classes of evidence for therapeutic
effectiveness, most data is of intermediate or
weak strength. Conclusion: This case highlights
diagnostic and clinical features of PACNS and
provides an overview of the current literature
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INTRODUCTION
Primary angiitis of the CNS (PACNS), also referred to
as primary CNS vasculitis (PCNSV), CNS vasculitis, and
previously, cerebral or primary granulomatous angiitis,
is an extremely rare but serious disease with an incidence
of 2.4 cases per one million person-years [1–3]. PACNS,
unlike other vasculitides, is confined to the CNS. HIV is
associated with various systemic vasculitides, from small
to large vessel, immune-mediated to infectious. However,
PACNS is less common than any systemic vasculitis
in both the general population as well as in patients
with HIV [4]. After an extensive literature review only
a few case reports of PACNS in HIV patients have been
identified [5, 6]. Further, in view of diagnostic advances
and updated classification, it is uncertain if these cases
represent true PACNS [7].
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PACNS remains a diagnostic challenge as presentation
varies from patient to patient and can range from strokes
to chronic headaches. It occurs with the same frequency
in men and women with a median age of 50 years and
may occur in both adult and pediatric patients [8, 9].
However, the presentation and treatment in pediatric
patients differs from that of adults [2, 8]. Therefore, this
review is limited to adult patients with PACNS.
The disease is characterized by inflammatory
infiltrates composed of lymphocytes, together with
necrosis limited to the medium and small vessels of the
CNS. The Calabrese diagnostic criteria were developed
over 20 years ago, however, MRI scan and pathology
are the best diagnostic tools as clinical findings are nonspecific and blood tests are usually normal [10]. Recently,
subtypes of PACNS have been identified; however,
classification remains a challenge [11]. Morbidity and
mortality are associated with cerebral infarctions and
involvement of large vessels. The prognosis has improved
since 1983, when Cupps et al. reported success using a
combination of cyclophosphamide and glucocorticoids
[12].
Today, treatment includes glucocorticoids and
cyclophosphamide, as it remains difficult to predict which
patients would do well with glucocorticoid monotherapy
[3, 12]. Cyclophosphamide has been shown to improve
survival [12]. The optimal duration of treatment is
unknown for this off-label use. Outcome is variable with
some patients fully recovering and others experiencing
permanent neurological damage. Toxicities associated
with cyclophosphamide include urothelial toxicity such
as cystitis, hematuria, bladder cancer, and infertility.
Glucocorticoid toxicity includes bone loss, osteoporosis,
diabetes mellitus, and Cushing ’s syndrome.
In patients intolerant to cyclophosphamide or those
who respond poorly to the drug, rituximab has been
used [2, 13]. Some patients receive weekly intramuscular
methotrexate maintenance therapy. Other alternatives
include azathioprine, chlorambucil, tocilizumab,
cyclosporine, aspirin, tumor necrosis factors (infliximab
and etanercept), and mycophenolate mofetil [1, 14–16].
We report a case of probable PACNS in a patient
with HIV treated successfully with cyclophosphamide
and pulse corticosteroids. Additionally, we conducted
a systematic literature review for PACNS and evaluated
the strength of the evidence using modified American
Academy of Neurology (AAN) classes of evidence for
therapeutic effectiveness criteria [17].

CASE REPORT
A 46-year-old female was admitted for headache,
vertigo, and an altered mental state. For several days
prior to presentation, she developed increasing confusion
and forgetfulness. She showed anterograde amnesia and
was not oriented to day or time. Her past medical history
included type 2 diabetes mellitus, HIV, hypertension,
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depression, and vertigo. Her home medications were
metformin 500 mg twice daily, insulin glargine 10 units
SQ nightly at bedtime, benazepril 20 mg once daily,
amlodipine 10 mg once daily, escitalopram 10 mg once
daily, atorvastatin 20 mg once daily, dolutegravir 50 mg
once daily, lamivudine-abacavir 300 mg/600 mg once
daily, and sulfamethoxazole-trimethoprim 800 mg/160
mg once daily. She also had a tooth extraction and a
cold several days prior to the onset of her presenting
symptoms. Her social history was positive for former
illicit substance abuse. In the emergency department,
she received acetaminophen 650 mg and meclizine 25
mg for symptom management. Her initial coagulation
studies, complete blood count, and chemistries were
unremarkable except for mild hyperglycemia (118 mg/
dL, N 74–106), hyperbilirubinemia (2.4 mg/dL, N 0.2–
1.3), and an ESR of 48 mm/hr (N 0–24). The patient’s
CD4 count was 1026 cells/mm3, hemoglobin A1C was
7.8, and vitamin B12 and TSH were within normal limits.
At this time the patient’s weight was 93 kg. Her initial
neurologic evaluation was non-focal apart from altered
mentation. She was admitted while a broad infectious
and inflammatory workup commenced.
A non-contrast computed tomography (CT) scan of the
head revealed a right occipital hypodensity with minimal
mass effect on the adjacent brain parenchyma and no
evidence of midline shift, most consistent with subacute
infarct, and was otherwise unremarkable appearing.
Subsequent brain magnetic resonance imaging
(MRI) scan with and without contrast revealed acute
infarcts in multiple vascular territories, including
infarcts in the right middle cerebral artery distribution,
left paramedian pons, bilateral occipital lobes, as well as
punctate infarcts in the posterior left frontal lobe (Figures
1 and 2). Vascular imaging revealed severe proximal
basilar artery stenosis, bilateral distal vertebral artery
stenosis, and moderate bilateral internal carotid artery
cavernous stenosis. A lumbar puncture was performed
and a cerebrospinal fluid (CSF) analysis was unrevealing
apart from lymphocytosis. Though a broad infectious
workup was negative, her clinical status worsened, and
she was started on cyclophosphamide for presumed CNS
vasculitis. Subsequent MRI scan revealed new infarcts
in the inferior right cerebellum in the distribution of the
right posterior inferior cerebellar artery, as well as in the
splenium of the corpus callosum, expansion of infarcts
in the right paramedian pons and corpus callosum, and
hemorrhagic conversion of the right occipital infarct.
A conventional angiogram was consistent with
vasculitis, and even though a brain biopsy was
performed, it did not capture a representative area
of inflammation that was seen on MRI. While tissue
diagnosis is considered the gold standard, repeat
biopsy was not pursued, as the risks did not outweigh
the benefits given the clinical context, high pretest
probability, and her response to treatment. Therefore,
she was diagnosed with probable PACNS based on her
fulminant course with multiple successive strokes in the
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setting of lymphocytic CSF pleocytosis, conventional
angiogram consistent with vasculitis, and absence of
systemic vasculitis. Furthermore, she was stabilized after
prolonged course of high dose steroids with additional
pulse dose cyclophosphamide. Additionally, her HIV was
controlled, with a CD4 count of 1026 cells/mm3, and she
was kept on daily pneumocystis jiroveci prophylaxis with
sulfamethoxazole-trimethoprim.
At the time of submission of this report, the patient
had received three cycles of cyclophosphamide therapy.
During the first cycle the patient received intravenous
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cyclophosphamide 1000 mg after hydration with 0.9%
NS, and premedication with ondansetron 16 mg IVPB for
nausea. The patient was started on prednisone 80 mg once
daily at the start of cyclophosphamide therapy, which was
continued upon discharge. Approximately four weeks
later, the patient was admitted again for the second cycle
of the same regimen. An MRI scan during this admission
showed stable infarcts compared to baseline. The patient
received the same premedication and intravenous
hydration as in cycle one. Approximately four weeks after
the second cycle, the patient was admitted for cycle three,
consisting of the same regimen as before. At this time she
was deemed to be neurologically stable and responding
well to treatment.

DISCUSSION

Figure 1: MRI brain diffusion imaging (DWI left, ADC on
right) revealing diffusion-positive strokes in multiple vascular
territories.

Figure 2: MRI brain (axial FLAIR slices) revealing multiple
areas of hyperintensity.

Central nervous system vasculitis can be classified
as primary or secondary [3, 18, 19]. It is primary
when there is no other involvement than the CNS and
secondary when it occurs with other inflammatory or
systemic conditions such as connective tissue diseases,
autoimmune or infectious diseases such as polyarteritis
nodosa, systemic lupus erythematosus, varicella zoster,
and HIV [9, 18]. The precise causes and pathogenesis of
PACNS are unknown.
Our patient was HIV positive but had no evidence
of systemic vasculitis or systemic symptoms such as
fever, weight loss, or malaise. Furthermore, there
was no alternative etiology to PACNS. HIV itself can
cause vasculitis, though this occurs as a consequence
of opportunistic infections such as cytomegalovirus,
meningitis, and mycobacterium avium [4, 9]. The
vasculitis is thought to be mainly the result of an
immune response. A pathogenic mechanism in HIV may
be interaction of T cell mediated cells, superantigens,
adhesion molecules, immune complexes, cytokines, and
growth factors [4, 20].
Secondary CNS vasculitis such as infections (e.g.
neurosyphilis), systemic vasculitis, and connective tissue
disease should be ruled out in cases of suspected PACNS.
Our patient did not have clinical or laboratory evidence
of such processes, e.g. the anemia, thrombocytopenia,
elevated liver enzymes, and low complement typically
associated with systemic vasculitis [21]. Infectious causes
of vasculitis were ruled out prior to placing the patient on
cyclophosphamide, which is immunosuppressive.
Diagnostic criteria for PACNS were suggested in 1987
by Calabrese and Mallek [21]. The differential diagnosis
is broad and includes reversible cerebral vasoconstriction
syndromes and systemic vasculitis [10, 22]. Reversible
vasoconstriction syndrome may be associated with
medications, hypertension, eclampsia or the postpartum
period, and is the most common mimicker of PACNS.
Other mimickers are listed in Table 1 [3, 21, 22–26].
Our patient presented with cognitive impairment
and headache, which constitute the two most common
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presenting symptoms, however, they are non-specific
and made diagnosis difficult. Focal neurological deficits
a common presenting symptom due to acute ischemic
events, were absent on initial presentation. Subsequent
cerebrovascular imaging was consistent with cerebral
vasculitis. Clinical features of PACNS are listed in Table 2
[3, 10, 24, 25, 27–29].
Our patient had involvement of the vertebral and
basilar arteries, a feature commonly reported with CNS
vasculitis [15]. Multiple ischemic infarctions visible on
MRI, which occur in 53% of patients, and intracranial
hemorrhages which occur in 9% of cases, were found
in our patient as well [1, 3]. Hemorrhage is caused by
vasculitis-induced blood vessel weakening or aneurysm
formation [24]. Thus, our patient can be included in the
most ominous subset of patients, i.e., rapidly progressive
PACNS.
A literature search was performed to retrieve all
publications describing medications used to treat
PACNS. The search was conducted in PubMed (1966–
March 2016), EMBASE (1980–2016), Ovid and the
Cochrane Library, and Google Scholar using the search
terms “primary angiitis”, “primary vasculitis”, “PACNS”,
“PCNSV”, and “primary cerebral or granulomatous
vasculitis”. No language or date restrictions were
considered. The FDA website was utilized for identification
and review of the latest prescribing information [30].
Included were randomized controlled trials, cohort
and case control studies, professional guidelines or
recommendations, case reports, case series, and studies
conducted on small numbers of patients. Preclinical
and chemical screening studies, review articles (other
than Meta-analysis or systematic reviews), letters to the
editor, editorials, and commentaries were excluded. For
each article identified, a second search was conducted
both in the databases above as well as by reviewing the
bibliography to locate additional articles. We included all
reports of patients more than or equal to 18-year-old.
To identify the strength of the evidence regarding
treatment for PACNS and evaluate evidence quality,
a modified AAN level of evidence classification for
therapeutic intervention was employed [17] using a threetiered system (i.e., strong, intermediate, weak). Strong
evidence involved prospective randomized controlled
trials or prospective matched group cohort studies
directly relevant or inclusion in a Guideline. Intermediate
evidence involved conflicting data in randomized clinical
trials or cohort studies, case-control studies, evidence in
the form of small or pilot trials or case series, or consensus
recommendation in the absence of relevant clinical trials
and better evidence than case reports. Weak evidence
involved isolated or anecdotal case reports, expert
opinion or where strong or intermediate evidence failed
to include dosages, relapse details, or patient outcomes.
Excluded was secondary vasculitis use or narrative
review articles or where the only available literature
regarding the use pertained to pre-clinical studies.
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Table 1: PACNS- The Great Masquerader- Conditions Mimicking
PACNS
Infections Associated With CNS Vasculitis
Viral (Human
immunodeficiency virus,
varicella-zoster,
cytomegalovirus)

Mycoplasma pneumoniae

Hepatitis

Borrelia burgdorferi

Bacterial endocarditis

Mycobacterium
tuberculosis

Acute bacterial meningitis

Rickettsia spp. (Rocky
Mountain spotted fever,
typhus)

Bartonella spp.

Fungal infections
(aspergillosis,
coccidiomycosis,
candidiasis)

Subarachnoid cysticercosis

Neurosyphilis

Systemic Vasculitides
Lymphoma (especially Hodgkin’s
disease)

Kawasaki disease

Polyarteritis nodosa

Giant cell arteritis

Henoch-Schonlein purpura

Takayasu’s arteritis

Wegener’s granulomatosis

Churg-Strauss
syndrome

Antineutrophil cytoplasmic antibodyassociated vasculitis

Behçet disease

Hypocomplementemic urticarial
vasculitis
Connective Tissue Diseases
Neuropsychiatric lupus

Mixed connective tissue disease

Rheumatoid arthritis

Dermatomyositis

Sjogren’s syndrome

Storage diseases

Inflammatory bowel disease Systemic lupus erythromatosis
Sarcoidosis

Cogan syndrome

Morphea or linear
scleroderma
Miscellaneous
Drug-induced cerebral
vasculitis—thiouracil, allopurinol,
minocycline, penicillamine,
carbamazepine, phenytoin,
methotrexate, isotrentino,
heroin, cyclosporine,
sympathomimetics such as
cocaine, ergotamine, ephedrine,
amphetamine, oxymetazoline,
phenylpropanolamine)

Graft versus host disease
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Moyamoya syndrome

Sneddon syndrome

Reversible posterior
leukoencephalopathy syndrome

MELAS (Mitochondrial
encephalomyopathy,
lactic acidosis, stroke)

Degos disease

Amyloid angiopathy

Table 2: Clinical and Diagnostic Characteristics of PACNS
Signs & Symptoms, Lab
and Imaging Findings

Percentage Our Patient

Headache

63

+

Cognitive Impairment

50

+

Hemiparesis

44

-

Pseudoxanthoma
elasticum

Stroke

40

+

Aphasia

28

-

Lipohyalinosis

Postpartum angiopathy

Transient ischemic attacks

28

-

Atypical multiple sclerosis

Optic neuritis

Ataxia

19

-

Seizures

16

-

Call—Fleming syndrome

CADASIL

Dysarthria

15

-

Migrainous vasospasm

Susac syndrome

Blurred or decreased visual
acuity

11

-

Whipple’s disease

CNS malignancy-related
angiitis

<10%

+

Amnesic syndrome

<10%

+

Lymphomonocytic pleocytosis

>90%

+

Brain biopsy evidence

75%

+

Mass lesions

15%

-

Fabry’s disease

Rasmussen encephalitis

Hodgkin’s and nonHodgkin’s lymphoma

Radiation vasculopathy

Intracranial dissection

Fibromuscular dysplasia

N-methyl-o-aspartate
receptor-mediated
encephalitis

648

Intracranial hemorrhage

Spinal cord involvement
Elevated ESR
Abnormal brain CT
Abnormal MRI

5%

-

<25%

+

50-60%

+

75%

+

Table 3: Published Clinical Research of PACNS in Adults
Drug

Results

Strength of Evidence

Reference

N = 163 patients

Favorable response 85% P alone;
80% C + P
C + P; increased mortality rate
27% of patients relapsed

-Intermediate evidence
- Cohort study
(retrospective)
(mostly same patients
as cohort below- study
extension)

Salvarani 2015

G alone- IV M 1 g (3–17 pulses, median 5),
then P 60 mg/day (median) for 0.4–107 mo
(median 9 mo)
N

Therapy

72

P+C

2

C

51

C PO 150 mg/day (1–33 mo)

23

C IV 1000 mg/mo (1–17 mo)

Azathioprine 100 mg/day (range 100–150
mg/day) for 0.4–76 mo (median 11 mo) + P
(6 patients)

Relapse less frequent in patients
treated with C + P versus P alone
(OR 2.9)
Higher disability scores and poor
response to treatment associated
with increasing age at time of
diagnosis (OR 1.44), cerebral
infarctions (OR 3.74), large vessel
involvement (OR 6.14)

Mycophenolate 2,000 mg/day (median) + P
(3 patients)
Rituximab 2 injections (1 patient)
N = 101 patients (over 21 years old period)
97 G
-25- 1 g M
-72- 60 mg P daily
49- I
-46 C PO 150 mg/day or IV 1 g/m2
-3 azathioprine

Favorable response 81%- G alone
85% - G + I
Relapses occurred in 25%

-Intermediate evidence
Salvarani 2007
-Retrospective chart review
(could not conclude if
necessary as group may
have initially had more
severe disease)
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Table 3: (Continued)
N= 52
- G (all but 1)- 7 as monotherapy (M for 3
pulses 250–1000 mg, then P 1 mg/kg for 23
mo
- 44 (85%) C
(Pulse IV 0.6–0.7 g/m2 Q2–4 wks for 3
pulses, then monthly for up to 12 pulses)
- 43 C+ G; 1 C alone
- Rituximab- 1 pt 375 mg/m2 weekly for 4
infusions (for C refractory disease)
- Azathioprine- after C induction- 22 pts; 2
mg/kg/day
-Methotrexate- 1 pt after induction
-Mycophenolate- 1pt after induction

Favorable response 32/49 pts (65) Intermediate evidence
Relapse 13/49 (27%)
Cohort study
Death 3 (6%)

De Boysson 2014

M + C IV; 12 mo therapy
(no dosages provided)

Initial response to M followed by
relapse at 3 weeks

Weak evidence
Case report

Rosenberg 2013

C IV + M (twice only-patient lost to followup)
(dosages not provided)

Beneficial effect; no relapse at 2
mo

Weak evidence
Case report

Bajij 2015

N=4; C + G

Weak evidence
Case reports (4)

Cupps 1983

Rituximab (2 IV doses of 1 g 2 weeks apart)
No relapses at 13 mo
+P
Methotrexate discontinued
(60 mg/day);
because of nausea and vomiting
P continued for 8 mo- lowered to 20 mg/day;
maintenance therapy with methotrexate IM
15 mg weekly for 5 mo + P 10 mg/day

Weak evidence
Case report

Salvarani 2014

TNF blockers- patients resistant to G + C
Infliximab 5 mg/kg single infusion
Etanercept 50 mg/week (for 20 mo); then 25
mg once weekly (for 8 mo)

Rapid/effective improvement
Etanercept arrested relapse
No relapses at 34 and 60 mo

Weak evidence
Case reports (2)

Salvarani 2008

N= 15
No dosages reported.
8 patients on G, 2 patients also on C (others
not reported)

1 patient on C+G improved after
Weak evidence
4 mo
Case series
1 patient on C+G died after 2
weeks
5 improved; 3 with residual effects
such as cortical blindness and
confusion

Rituximab effective for C
refractory disease
Patients receiving methotrexate or
mycophenolate remained free of
disease
Neurological damage persisted for
82% of pts

Lie 1992

C = cyclophosphamide
P= prednisone PO
M= methylprednisolone IV
G= glucocorticoids
I= immunosuppressants

Most of the medications have only intermediate or
weak evidence consisting of several small retrospective
cohort studies and case reports (Table 3). The vast
majority of literature pertains to systemic or secondary
vasculitis with PACNS treatment recommendations
derived from systemic vasculitis. No clinical trials in
PACNS have been conducted. There is one cohort of 101
patients and a second cohort that extends the follow-up
and includes some additional patients (N=163) [1, 2].
These cohorts constitute intermediate evidence. All other
literature retrieved regarding PACNS pharmacotherapy
pertains to weak evidence.

Cyclophosphamide and glucocorticoids remain
the standard of care. Cytotoxic agents have been used
for CNS vasculitis for decades based on therapeutic
protocols in systemic vasculitides, anecdotal reports
and cohort studies with favorable results [12]. The use
of cyclophosphamide was first described in 1978 for use
in secondary vasculitis [31]. The mechanism appears
to be autoantibody suppression. However, no clinical
trials have been conducted and it is unknown whether
cyclophosphamide is the most effective and least toxic
cytotoxic agent.
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There is controversy regarding whether to
administer glucocorticoids as monotherapy or to add
cyclophosphamide. In 163 patients with PACNS, a
favorable response was observed in 80% of patients
treated with prednisone and cyclophosphamide versus
85% in patients treated with prednisone alone [2].
Prednisone alone was associated with more frequent
relapses but relapses were not associated with rapid
therapy withdrawal. It was noted that cerebral infarcts
were associated with poor treatment responses.
Predominant involvement of medium-sized vessels, as in
our patient, may be less likely to respond to glucocorticoid
monotherapy [25]. In addition to the presence of cerebral
infarcts, large vessel involvement, focal neurological
deficits and cognitive impairment are associated with
increased mortality [1].
Prednisone should be initiated as soon as the diagnosis
of PACNS is made at a single or divided dose of 1 mg/
kg/day orally. If the patient does not respond promptly,
cyclophosphamide should be added. In life-threatening
or severe/progressive cases and/or for disease flares,
pulse parenteral methylprednisolone at 1 g for three days
may be used but no evidence exists this is more effective
than oral prednisone [3].
In addition to controversy over whether to add C,
controversy also exists as to whether cyclophosphamide
should be given as continuous oral therapy or intravenous
pulse therapy and no trials have been conducted to answer
this question. The goal of pulse therapy is to minimize
cyclophosphamide exposure. In systemic vasculitis trials,
intravenous cyclophosphamide was as effective and
produced less leucopenia than oral cyclophosphamide
in inducing remission [31, 32]. Relapse rates were not
reported in either study [31, 32]. In another study, a
higher relapse rate was observed with IV pulse use and
adverse effects were more frequent with continuous oral
cyclophosphamide [33]. However, that study investigated
relatively short courses of treatment. There is some
evidence that prolonged treatment with low-dose pulse
cyclophosphamide for 18–24 months may reduce the rate
of relapse [34]. Again, all these studies are in systemic
vasculitis, not PACNS.
The pulse dose is monthly infusions of 15 mg/kg or
500 to 1000 mg/m2 [24, 35]. The median oral dose of
cyclophosphamide has been reported to be 150 mg/day
with a range of 75–150 mg/day for a median duration
of seven months with a range of 1–33 months [2]. An
oral dosage of 2 mg/kg/day is frequently used. While
the results of those trials are inconclusive, in other
vasculitides, oral cyclophosphamide was successful when
given for 3–6 months. Dosages should be adjusted for age
and renal dysfunction [3].
Cyclophosphamide may result in life-threatening
infections, cancer (particularly of the bladder or secondary
lymphomas), hemorrhagic cystitis, and infertility.
Bladder toxicity and myelodysplastic syndrome greatly
increase with cumulative doses > 30 g [35]. Carcinoma
of the renal pelvis was reported in a patient receiving
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long-term cyclophosphamide for cerebral vasculitis
[36]. Immunosuppression from cyclophosphamide can
result in serious, sometimes fatal infections and the
degree of neutropenia correlates with reduced resistance
to infections. Patients should receive pneumocystis
prophylaxis with oral sulfamethoxazole/trimethoprim.
Other supportive therapy includes antiemetics and
normal saline hydration. While plasmapheresis is
ineffective, intravenous immunoglobulin (IVIG) has been
successful in some refractory patients [37].
While glucocorticoids remain the standard of care for
remission, in patients unable to take cyclophosphamide,
rituximab at a dose of 1 gm for two doses administered two
weeks apart has been used. A double blind randomized
trial in systemic vasculitis comparing rituximab to
cyclophosphamide, found rituximab non-inferior to
cyclophosphamide for remission induction and more
effective for inducing remission of relapsing disease (67%
versus 42%, p=0.01) [38].
After induction, many advocate switching to a low
risk immunosuppressant to minimize cyclophosphamide
exposure [3, 24, 29, 39]. The induction-maintenance
strategy has been used in secondary vasculitis using
azathioprine at 1–2 mg/kg/day [40]. In a recent study,
azathioprine was used in 25% of patients for maintenance
therapy,
following
cyclophosphamide
induction.
However, in PACNS a treatment course for 12–18
months, preferably 18, is used in most patients assuming
relapses do not mandate prolonged therapy [3, 21].
Some continue maintenance therapy for 2–3 years [22].
Other agents include methotrexate at 20–25 mg/week,
or mycophenolate mofetil at 1–2 g/day once remission
has been obtained [3]. Comparison of methotrexate and
azathioprine in patients with systemic vasculitis have
not shown either to be superior, however, methotrexate
does not penetrate the CNS well [29]. Methotrexate
dosage should be reduced in patients with severe renal
impairment [41].
In treatment-resistant cases, tumor necrosis factor α
blockers (e.g. infliximab 5 mg/kg or etanercept 50 mg/
week) and mycophenolate mofetil (2 g/day) have been
used. A relapse rate of approximately 25% may occur with
serial MRI scan or MRA follow-up at 4th–6th week and at
3rd–4th month intervals thereafter [3, 16, 25].

CONCLUSION
Primary angiitis of the central nervous system is a
rare but serious disease that presents both diagnostic and
therapeutic challenges. Favorable neurological outcome
is a realistic goal. Knowledge regarding the epidemiology,
pathogenesis, diagnosis and management continues
to evolve. Optimal management remains uncertain.
Pulse cyclophosphamide treatment and identification of
patients to initially receive immunosuppressant therapy
and alternatives require further investigation.
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